suramin has been researched along with Angiogenesis, Pathologic in 40 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study was to explore the inhibitory effect of angiogenesis inhibitor Suramin in combination with cisplatin (DDP) on the growth and lung metastasis of lung adenocarcinoma LA795 cell xenografts in mice." | 7.73 | [Effects of suramin in combination with cisplatin on growth and metastasis of lung adenocarcinoma xenografts in mice]. ( He, JB; Ou, LW; Wang, XH; Zhang, P, 2006) |
| "Suramin is a polysulfonated naphthylurea with multiple potential mechanisms of action against tumors, including the ability to bind growth factors known to promote tumor angiogenesis." | 6.69 | A pilot trial of suramin in metastatic breast cancer to assess antiangiogenic activity in individual patients. ( Benson, AB; Bouck, N; Cisneros, A; French, S; Gradishar, WJ; Liu, J; Rademaker, A; Soff, G, 2000) |
| " Additionally, we compared the antitumoral effect of protamine with that of another inhibitor of angiogenesis, suramin, and investigated a potential synergistic antitumoral action of low doses of protamine combined with the antineoplastic carmustine." | 5.30 | Protamine inhibits angiogenesis and growth of C6 rat glioma; a synergistic effect when combined with carmustine. ( Arrieta, O; Guevara, P; Ortiz, A; Rembao, D; Reyes, S; Sotelo, J, 1998) |
| " This study was to explore the inhibitory effect of angiogenesis inhibitor Suramin in combination with cisplatin (DDP) on the growth and lung metastasis of lung adenocarcinoma LA795 cell xenografts in mice." | 3.73 | [Effects of suramin in combination with cisplatin on growth and metastasis of lung adenocarcinoma xenografts in mice]. ( He, JB; Ou, LW; Wang, XH; Zhang, P, 2006) |
| "Suramin is a polysulfonated naphthylurea with multiple potential mechanisms of action against tumors, including the ability to bind growth factors known to promote tumor angiogenesis." | 2.69 | A pilot trial of suramin in metastatic breast cancer to assess antiangiogenic activity in individual patients. ( Benson, AB; Bouck, N; Cisneros, A; French, S; Gradishar, WJ; Liu, J; Rademaker, A; Soff, G, 2000) |
| " The dose-response relationship for an inhibitor is studied using images of endothelial cells captured in vitro by Matrigel assay." | 1.39 | Mesh-loosening quantification of inhibition of angiogenic tube formation through image analysis. ( Gotoh, T; Minamikawa-Tachino, R; Ogura, K, 2013) |
| "Suramin inhibited the proliferation of pancreatic cancer cells in a dose-dependent manner and reduced viability at high concentrations." | 1.34 | Suramin inhibits not only tumor growth and metastasis but also angiogenesis in experimental pancreatic cancer. ( Bhargava, S; Buhr, HJ; Hines, OJ; Hotz, B; Hotz, HG; Reber, HA, 2007) |
| "Suramin tended to increase CAM vasculature at 50 microg but caused dramatic reductions both in vessel length and CAM growth at 100 microg." | 1.32 | A novel early chorioallantoic membrane assay demonstrates quantitative and qualitative changes caused by antiangiogenic substances. ( Hazel, SJ, 2003) |
| "Suramin is a polysulfonated naphthylurea that inhibits tumor cell proliferation and angiogenesis, but the widespread use of this drug has been limited by significant neurologic toxicity." | 1.31 | Suramin analogs inhibit human angiogenesis in vitro. ( Flattmann, GJ; Gagliardi, AR; Meyers, MO; Su, JL; Wang, YZ; Woltering, EA, 2000) |
| " Additionally, we compared the antitumoral effect of protamine with that of another inhibitor of angiogenesis, suramin, and investigated a potential synergistic antitumoral action of low doses of protamine combined with the antineoplastic carmustine." | 1.30 | Protamine inhibits angiogenesis and growth of C6 rat glioma; a synergistic effect when combined with carmustine. ( Arrieta, O; Guevara, P; Ortiz, A; Rembao, D; Reyes, S; Sotelo, J, 1998) |
| "A new therapeutic strategy for treating metastasis in hepatocellular carcinoma (HCC) has entailed the use of antiangiogenic agents such as suramin, BB-94 (Batimastat), TNP-470, and carboxyamido-triazole (CAI, a synthetic inhibitor of non-excitable calcium channels that reversibly inhibits angiogenesis)." | 1.30 | Effect of antiangiogenic agents on experimental animal models of hepatocellular carcinoma. ( Bu, W; Li, XM; Qin, LX; Tang, ZY; Xia, JL, 1999) |
| "(c) Suramin-treated rats had markedly decreased lymphocyte stimulation, pointing to a possible immunosuppressive effect." | 1.30 | Effects of suramin on anastomotic colon tumors in a rat model. ( De Clerck, LS; Dirix, L; Eyskens, E; Hendriks, J; Hubens, A; Hubens, G; Lauwers, P; Schuerwegh, A; Stevens, WJ; Van Marck, E; Vermeulen, P, 1999) |
| "Suramin was also studied in an in vivo model of tumour-induced angiogenesis using the murine M5076 reticulosarcoma, a tumour producing significant levels of bFGF." | 1.28 | Suramin prevents neovascularisation and tumour growth through blocking of basic fibroblast growth factor activity. ( Grandi, M; Mongelli, N; Pesenti, E; Sola, F; Spreafico, F, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 25 (62.50) | 18.2507 |
| 2000's | 13 (32.50) | 29.6817 |
| 2010's | 2 (5.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Acero, N | 1 |
| Braña, MF | 1 |
| Añorbe, L | 1 |
| Domínguez, G | 1 |
| Muñoz-Mingarro, D | 1 |
| Mitjans, F | 1 |
| Piulats, J | 1 |
| Santos, AF | 1 |
| Zaltsman, AB | 1 |
| Martin, RC | 1 |
| Kuzmin, A | 1 |
| Alexandrov, Y | 1 |
| Roquemore, EP | 1 |
| Jessop, RA | 1 |
| van Erck, MG | 1 |
| Verheijen, JH | 1 |
| Minamikawa-Tachino, R | 1 |
| Ogura, K | 1 |
| Gotoh, T | 1 |
| Marchetti, D | 1 |
| Reiland, J | 1 |
| Erwin, B | 1 |
| Roy, M | 1 |
| Hazel, SJ | 1 |
| Hunziker, EB | 1 |
| Driesang, IM | 1 |
| Berger, AC | 1 |
| Wang, XQ | 1 |
| Zalatoris, A | 1 |
| Cenna, J | 1 |
| Watson, JC | 1 |
| Takano, S | 2 |
| Zhang, P | 1 |
| He, JB | 1 |
| Ou, LW | 1 |
| Wang, XH | 1 |
| Guo, K | 1 |
| Li, J | 1 |
| Wang, H | 1 |
| Osato, M | 1 |
| Tang, JP | 1 |
| Quah, SY | 1 |
| Gan, BQ | 1 |
| Zeng, Q | 1 |
| Bahramsoltani, M | 1 |
| Plendl, J | 1 |
| Bhargava, S | 1 |
| Hotz, B | 1 |
| Hines, OJ | 1 |
| Reber, HA | 1 |
| Buhr, HJ | 1 |
| Hotz, HG | 1 |
| Gil, M | 1 |
| Skopińska-Rózewska, E | 1 |
| Radomska, D | 1 |
| Demkow, U | 1 |
| Skurzak, H | 1 |
| Rochowska, M | 1 |
| Beuth, J | 1 |
| Roszkowski, K | 1 |
| Ciomei, M | 2 |
| Pastori, W | 1 |
| Mariani, M | 1 |
| Sola, F | 2 |
| Grandi, M | 2 |
| Mongelli, N | 3 |
| Gately, S | 1 |
| Neville, ME | 1 |
| Herblin, WF | 1 |
| Gross, JL | 1 |
| Engelhard, H | 1 |
| Perricone, M | 1 |
| Eidsvoog, K | 1 |
| Brem, S | 1 |
| Braddock, PS | 1 |
| Hu, DE | 2 |
| Fan, TP | 2 |
| Stratford, IJ | 1 |
| Harris, AL | 2 |
| Bicknell, R | 3 |
| Pepper, MS | 1 |
| Vassalli, JD | 1 |
| Wilks, JW | 1 |
| Schweigerer, L | 1 |
| Orci, L | 1 |
| Montesano, R | 1 |
| Garrido, T | 1 |
| Riese, HH | 1 |
| Aracil, M | 1 |
| Pérez-Aranda, A | 1 |
| Coomber, BL | 1 |
| Firsching, A | 1 |
| Nickel, P | 1 |
| Mora, P | 1 |
| Allolio, B | 1 |
| Danesi, R | 1 |
| Del Bianchi, S | 1 |
| Soldani, P | 1 |
| Campagni, A | 1 |
| La Rocca, RV | 1 |
| Myers, CE | 1 |
| Paparelli, A | 1 |
| Del Tacca, M | 1 |
| Zhang, H | 1 |
| Moghaddam, A | 1 |
| Fox, S | 1 |
| Scott, P | 1 |
| Pattison, A | 1 |
| Gatter, K | 1 |
| Stratford, I | 1 |
| Okada, N | 1 |
| Fushimi, M | 1 |
| Nagata, Y | 1 |
| Fukunaga, T | 1 |
| Tsutsumi, Y | 1 |
| Nakagawa, S | 1 |
| Mayumi, T | 1 |
| Johnson, JP | 1 |
| Bruce, JN | 1 |
| Kakeji, Y | 1 |
| Teicher, BA | 1 |
| Morris, AD | 1 |
| Léonce, S | 1 |
| Guilbaud, N | 1 |
| Tucker, GC | 1 |
| Pérez, V | 1 |
| Jan, M | 1 |
| Cordi, AA | 1 |
| Pierré, A | 1 |
| Atassi, G | 1 |
| Weiss, GR | 1 |
| Burris, HA | 1 |
| Eckhardt, SG | 1 |
| Rodriguez, GI | 1 |
| Sharma, S | 1 |
| Valley, A | 1 |
| Manetti, F | 1 |
| Cappello, V | 1 |
| Botta, M | 1 |
| Corelli, F | 1 |
| Biasoli, G | 1 |
| Borgia, AL | 1 |
| Arrieta, O | 1 |
| Guevara, P | 1 |
| Reyes, S | 1 |
| Ortiz, A | 1 |
| Rembao, D | 1 |
| Sotelo, J | 1 |
| Qin, LX | 1 |
| Tang, ZY | 1 |
| Li, XM | 1 |
| Bu, W | 1 |
| Xia, JL | 1 |
| Lauwers, P | 1 |
| Hubens, G | 1 |
| Hendriks, J | 1 |
| Vermeulen, P | 1 |
| Schuerwegh, A | 1 |
| Stevens, WJ | 1 |
| De Clerck, LS | 1 |
| Dirix, L | 1 |
| Van Marck, E | 1 |
| Hubens, A | 1 |
| Eyskens, E | 1 |
| Gradishar, WJ | 1 |
| Soff, G | 1 |
| Liu, J | 1 |
| Cisneros, A | 1 |
| French, S | 1 |
| Rademaker, A | 1 |
| Benson, AB | 1 |
| Bouck, N | 1 |
| Meyers, MO | 1 |
| Gagliardi, AR | 1 |
| Flattmann, GJ | 1 |
| Su, JL | 1 |
| Wang, YZ | 1 |
| Woltering, EA | 1 |
| Krüger, EA | 1 |
| Figg, WD | 1 |
| Weckbecker, G | 1 |
| Liu, R | 1 |
| Tolcsvai, L | 1 |
| Pesenti, E | 1 |
| Spreafico, F | 1 |
| Gagliardi, A | 1 |
| Hadd, H | 1 |
| Collins, DC | 1 |
| Wellstein, A | 1 |
| Zugmaier, G | 1 |
| Califano, JA | 1 |
| Kern, F | 1 |
| Paik, S | 1 |
| Lippman, ME | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Controlled Trial of Neo-adjuvant Progesterone and Vitamin D3 in Women With Large Operable Breast Cancer and Locally Advanced Breast Cancer.[NCT01608451] | Phase 3 | 800 participants (Actual) | Interventional | 2007-09-30 | Terminated (stopped due to Slow accrual implies that clinical questions being questioned have lost its significance.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for suramin and Angiogenesis, Pathologic
| Article | Year |
|---|---|
[Anti-angiogenesis treatment for brain tumors--present and future].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Clinical Tr | 2005 |
Vascular targeting and the inhibition of angiogenesis.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Antineoplastic Agents; Cyclohexanes; Endothel | 1994 |
Breast cancer angiogenesis--new approaches to therapy via antiangiogenesis, hypoxic activated drugs, and vascular targeting.
Topics: Angiogenesis Inducing Agents; Breast Neoplasms; Female; Genetic Therapy; Humans; Neovascularization, | 1996 |
Angiogenesis in human gliomas: prognostic and therapeutic implications.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cyclohexanes; Endothelial Growth Factors; Epidermal | 1997 |
New anticancer agents.
Topics: Animals; Antineoplastic Agents; Dacarbazine; Humans; Lactones; Macrolides; Neovascularization, Patho | 1997 |
1 trial available for suramin and Angiogenesis, Pathologic
| Article | Year |
|---|---|
A pilot trial of suramin in metastatic breast cancer to assess antiangiogenic activity in individual patients.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule; Female | 2000 |
34 other studies available for suramin and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Synthesis and biological evaluation of novel indolocarbazoles with anti-angiogenic activity.
Topics: Angiogenesis Inhibitors; Animals; Capillaries; Cell Line, Tumor; Cell Proliferation; Collagen; Drug | 2012 |
Angiogenesis: an improved in vitro biological system and automated image-based workflow to aid identification and characterization of angiogenesis and angiogenic modulators.
Topics: Angiogenesis Modulating Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Automatio | 2008 |
Mesh-loosening quantification of inhibition of angiogenic tube formation through image analysis.
Topics: Angiogenesis Inhibitors; Animals; Cell Line; Dose-Response Relationship, Drug; Endothelial Cells; Im | 2013 |
Inhibition of heparanase activity and heparanase-induced angiogenesis by suramin analogues.
Topics: Antineoplastic Agents; Cell Division; Dose-Response Relationship, Drug; Glucuronidase; Humans; Neopl | 2003 |
A novel early chorioallantoic membrane assay demonstrates quantitative and qualitative changes caused by antiangiogenic substances.
Topics: Allantois; Amiloride; Angiogenesis Inhibitors; Animals; Blood Vessels; Chick Embryo; Chorion; Cycloh | 2003 |
Functional barrier principle for growth-factor-based articular cartilage repair.
Topics: Angiogenesis Inhibitors; Animals; Cartilage, Articular; Cell Division; Chondrocytes; Chondrogenesis; | 2003 |
A murine model of ex vivo angiogenesis using aortic disks grown in fibrin clot.
Topics: Animals; Aorta; Cell Proliferation; Cell Separation; Endostatins; Endothelium, Vascular; Fibrin; Flo | 2004 |
[Effects of suramin in combination with cisplatin on growth and metastasis of lung adenocarcinoma xenografts in mice].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cisplatin; Drug Synergi | 2006 |
PRL-3 initiates tumor angiogenesis by recruiting endothelial cells in vitro and in vivo.
Topics: Animals; Blood Vessels; Cell Movement; CHO Cells; Coculture Techniques; Colorectal Neoplasms; Cricet | 2006 |
Different ways to antiangiogenesis by angiostatin and suramin, and quantitation of angiostatin-induced antiangiogenesis.
Topics: Angiogenesis Inhibitors; Angiostatins; Animals; Antineoplastic Agents; Endothelium, Vascular; Neopla | 2007 |
Suramin inhibits not only tumor growth and metastasis but also angiogenesis in experimental pancreatic cancer.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor | 2007 |
Effect of purinergic receptor antagonists suramin and theobromine on tumor-induced angiogenesis in BALB/c mice.
Topics: Animals; Carcinoma; Injections, Subcutaneous; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Neopl | 1993 |
New sulfonated distamycin A derivatives with bFGF complexing activity.
Topics: 3T3 Cells; Animals; Binding, Competitive; Distamycins; Fibroblast Growth Factor 2; Mice; Mice, Inbre | 1994 |
Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator.
Topics: Animals; Cell Division; Cell Movement; Chick Embryo; Cornea; Drug Screening Assays, Antitumor; Endot | 1994 |
A structure-activity analysis of antagonism of the growth factor and angiogenic activity of basic fibroblast growth factor by suramin and related polyanions.
Topics: Animals; Capillaries; Cattle; Cell Division; Cells, Cultured; Dose-Response Relationship, Drug; Endo | 1994 |
Modulation of bovine microvascular endothelial cell proteolytic properties by inhibitors of angiogenesis.
Topics: Adrenal Cortex; Animals; Betamethasone; Cattle; Cell Division; Cells, Cultured; Endopeptidases; Endo | 1994 |
Suppression of VEGF-induced angiogenesis by the protein tyrosine kinase inhibitor, lavendustin A.
Topics: Animals; Antibodies, Monoclonal; Endothelial Growth Factors; Fibroblast Growth Factor 2; Lymphokines | 1995 |
Endothelial cell differentiation into capillary-like structures in response to tumour cell conditioned medium: a modified chemotaxis chamber assay.
Topics: Adenocarcinoma; Animals; Antibodies; Aorta; Breast Neoplasms; Capillaries; Cattle; Cell Differentiat | 1995 |
Suramin inhibits C6 glioma-induced angiogenesis in vitro.
Topics: Analysis of Variance; Animals; Cattle; Cell Division; Chemotaxis; Culture Media, Conditioned; Cultur | 1995 |
Antiproliferative and angiostatic activity of suramin analogues.
Topics: Antineoplastic Agents; Cell Division; Humans; Neoplasms; Neovascularization, Pathologic; Structure-A | 1995 |
Suramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane.
Topics: Allantois; Animals; Cattle; Cell Division; Cells, Cultured; Chick Embryo; Chorion; Endothelium, Vasc | 1993 |
Evaluation of angiogenic inhibitors with an in vivo quantitative angiogenesis method using agarose microencapsulation and mouse hemoglobin enzyme-linked immunosorbent assay.
Topics: Animals; Carcinoma, Squamous Cell; Cortodoxone; Drug Compounding; Drug Evaluation, Preclinical; Enzy | 1996 |
Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents.
Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Anti | 1997 |
Eriochrome Black T, structurally related to suramin, inhibits angiogenesis and tumor growth in vivo.
Topics: Animals; Antineoplastic Agents; Azo Compounds; Cell Division; Drug Screening Assays, Antitumor; Fema | 1997 |
Synthesis and binding mode of heterocyclic analogues of suramin inhibiting the human basic fibroblast growth factor.
Topics: 3T3 Cells; Allantois; Animals; Antineoplastic Agents; Chorion; Drug Screening Assays, Antitumor; Fib | 1998 |
Protamine inhibits angiogenesis and growth of C6 rat glioma; a synergistic effect when combined with carmustine.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Division; Dose-Response Relationship, D | 1998 |
Effect of antiangiogenic agents on experimental animal models of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Cell Division; Cyclohexanes; Liver Neoplasms, Experimental; Mice; Mi | 1999 |
Effects of suramin on anastomotic colon tumors in a rat model.
Topics: Adenocarcinoma; Anastomosis, Surgical; Animals; Antineoplastic Agents; Cell Survival; Colon; Colonic | 1999 |
Suramin analogs inhibit human angiogenesis in vitro.
Topics: Animals; Cells, Cultured; Dose-Response Relationship, Drug; Female; Humans; Neovascularization, Path | 2000 |
Protein binding alters the activity of suramin, carboxyamidotriazole, and UCN-01 in an ex vivo rat aortic ring angiogenesis assay.
Topics: Alkaloids; Angiogenesis Inhibitors; Animals; Aorta, Thoracic; Biological Assay; Blood Proteins; Dose | 2001 |
Intradermal angiogenesis in nude mice induced by human tumor cells or b-FGF.
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Carcinoma, Squamous Cell; Cell Line; Female; Fibroblast G | 1992 |
Suramin prevents neovascularisation and tumour growth through blocking of basic fibroblast growth factor activity.
Topics: Animals; Female; Fibroblast Growth Factor 2; Hemoglobins; Heparin; Lymphoma, Large B-Cell, Diffuse; | 1992 |
Inhibition of angiogenesis by suramin.
Topics: Allantois; Animals; Chick Embryo; Chorion; Dose-Response Relationship, Drug; Heparin; Neovasculariza | 1992 |
Tumor growth dependent on Kaposi's sarcoma-derived fibroblast growth factor inhibited by pentosan polysulfate.
Topics: Adrenal Gland Neoplasms; Animals; Breast Neoplasms; Cell Division; Endothelium, Vascular; Female; Fi | 1991 |